Evidence map›Paper›PMID 42005429›Full record

ReviewBMJ medicine2026

Vaccine cold chain and understanding what underpins vaccine security for vaccine preventable diseases.

Gilbert Rukundo, Matthew Moore, Herve Semukunzi, Sudeshna Chatterjee, Jean Pierre Musabyimana, Claude Mambo Muvunyi, Christopher Aird Green

Erratum issuedAbstract readReview
In one paragraph

Review in BMJ medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Gilbert RukundoSchool of Chemical Engineering, College of Engineering and Physical Sciences, University of Birmingham, Birmingham, UK.
Matthew MooreSchool of Chemical Engineering, College of Engineering and Physical Sciences, University of Birmingham, Birmingham, UK.
Herve SemukunziSchool of Chemical Engineering, College of Engineering and Physical Sciences, University of Birmingham, Birmingham, UK.
Sudeshna ChatterjeeSchool of Chemical Engineering, College of Engineering and Physical Sciences, University of Birmingham, Birmingham, UK.
Jean Pierre MusabyimanaRwanda Biomedical Centre, Kigali, Rwanda.
Claude Mambo MuvunyiUniversity of Rwanda, Kigali, Rwanda.
Christopher Aird GreenSchool of Chemical Engineering, College of Engineering and Physical Sciences, University of Birmingham, Birmingham, UK.ORCID https://orcid.org/0000-0002-1984-4014

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines have saved an estimated 154 million lives in the past 50 years and support 15 of the 17 United Nations sustainable development goals. Vaccines are also an important tool in the control of new outbreaks of infectious diseases. The vaccine cold chain, however, is key in enabling and empowering implementation of vaccine policy and societal protection from all vaccine preventable diseases, and is especially relevant in low and middle income countries in sub-Saharan Africa. The vaccine cold chain is a complex, highly specialised, temperature controlled supply chain network that extends from the point of vaccine manufacture to dose administration, and has multiple points of vulnerability. Large quantities of vaccines are lost because of excess heat or accidental freezing, resulting in missed opportunities for vaccination. Disruption to the provision of routine vaccines during the covid-19 pandemic resulted in millions of children not being vaccinated. The vaccine cold chain needs strategic prioritisation for investment and innovation so that the next generation of vaccine cold chains for low and middle income countries can be designed towards providing reliable and sustainable vaccine security in an uncertain world of climate change, managing the advent of new vaccine technologies, and narrowing inequalities in global health for resource poor communities. This review focuses on the vaccine cold chain in African low and middle income countries, and how new and emerging advances in vaccine science and challenges will affect the readiness to control the burden of vaccine preventable disease on the continent.

Indexed as

Community health servicesInfectious disease medicinePublic health

Identifiers

PMID42005429
PMCPMC13084896

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.